Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Exosomal miR-20a-5p derived from cisplatin-resistant osteosarcoma cells promotes chemoresistance via Inhibition of
Peng Zhang1,2, Luyue Deng3, Kai Chen3
1Bone and Soft Tissue Sarcoma Department, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. hnszlyybst@126.com.
Abstract:
Cisplatin resistance continues to pose a significant challenge in the treatment of osteosarcoma, markedly impairing clinical outcomes. Accumulating evidence indicates that exosomal microRNAs (miRNAs) facilitate intercellular communication and play a critical role in drug resistance mechanisms. In this study, we conducted high-throughput sequencing of serum-derived exosomes and identified miR-20a-5p as significantly upregulated in cisplatin-resistant osteosarcoma patients. Functional analyses revealed that exosomes enriched with miR-20a-5p derived from cisplatin-resistant HOS cells (HOS-DDP) were internalized by sensitive HOS cells, thereby promoting cisplatin resistance through the inhibition of ferroptosis. Mechanistically, co-culture with miR-20a-5p - rich exosomes resulted in preserved mitochondrial morphology, reduced Fe2+ and ROS accumulation, increased GSH levels, and suppressed T-SOD depletion under cisplatin-induced stress. Furthermore, exosomal miR-20a-5p was demonstrated to directly target and suppress the tumor suppressor RUNX3, a key regulator of ferroptotic pathways. Overexpression of RUNX3 restored ferroptosis and reversed the miR-20a-5p-mediated resistance phenotypes. Collectively, these findings elucidated that exosomal miR-20a-5p conferred cisplatin resistance in osteosarcoma by inhibiting ferroptosis via RUNX3 suppression, providing a promising therapeutic target for overcoming chemoresistance.
More Related Videos
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Related Concept Videos
Treatment Resistant Cancers
MicroRNAs
MicroRNAs